To The Moon

$BYD COMPANY(01211)$ is set to release its financial results on August 28. The market expects Q2 revenue of RMB 211.7 billion, representing year‑on‑year growth of approximately 24.3%. Adjusted earnings per share are projected at RMB 0.79, down 24% year‑on‑year. In terms of valuation, the current P/E ratio stands at 27.67x, which is at a relatively high level over the past three years, yet still below the industry average of 33.67x. Looking at the revenue structure, BYD's income primarily comes from two segments: automobiles and related products, and mobile handset components and assembly. Automobiles are the main revenue source, accounting for about 84% of total revenue. In terms of sales volume, BYD disclosed that it delivered a

This morning, Innovent Biologics surged sharply, at one point rising over 12% to hit a record high of HK$112.6, with its market capitalization exceeding HK$190 billion, making it the second pharmaceutical stock this year, after WuXi AppTec, to reach an all-time high. On the news front, Innovent Biologics released its earnings report on August 25. The company posted first-half revenue of RMB 8.6 billion, up 45% year-on-year, slightly missing Bloomberg consensus estimates by 1.1%. The company’s adjusted comparable net profit reached RMB 1.25 billion, exceeding the Bloomberg consensus of RMB 896 million and already surpassing the full-year level of the previous year. In addition, the company clearly set a 2030 revenue target of RMB 35–40 billion. Over the past ten months, Innovent Biologics h

According to sources close to the matter, as Alibaba launched a placement financing round, founder Jack Ma has been increasing his holdings in Alibaba's Hong Kong-listed shares for several consecutive days, with the total amount exceeding HK$600 million, signaling his strong confidence in Alibaba's AI prospects. In addition, after Joseph Tsai purchased approximately HK$80 million worth of Alibaba shares yesterday, on August 25, according to information from the Hong Kong Stock Exchange, Alibaba Group Chairman Joseph Tsai again increased his stake by about HK$82 million. Following the placement news, Tsai has bought Alibaba shares for two consecutive days, and his current holdings amount to approximately HK$160 million. Are Jack Ma and Joseph Tsai's successive share purchases a genuine vote

Innovative drugs surge: Is earnings growth driving a sector value revaluation? Today, Hong Kong-listed innovative drug stocks rallied sharply, with WuXi XDC soaring over 14%, Asymchem jumping 16.83%, and Insilico Medicine rising 12.87%. On the news front, WuXi XDC and Asymchem just released their interim 2026 results. For WuXi XDC, first-half revenue reached RMB 3.701 billion, up 37.0% year-on-year, in line with market expectations; net profit attributable to shareholders was RMB 819 million, up 9.9%; adjusted net profit attributable to shareholders was RMB 1.027 billion, up 37.4%, essentially matching revenue growth and indicating sound earnings quality. Gross margin was 37.0%, up 0.9 percentage points year-on-year. Order backlog remained robust, with unfilled service orders of approximat

$阿里巴巴(BABA)$'s HK$80 billion placement plan landed, and the Hong Kong stock tumbled more than 10% immediately, with the price pushed right down to the placement price. Right at this panicked moment, Joe Tsai and Eddie Wu jointly bought 1.07 million shares, spending HK$120 million – the timing is strikingly precise. On one hand, the share price collapse from the placement; on the other, two core executives stepping in simultaneously – this kind of move is hard to chalk up to coincidence. If it's about buying on bad news, the purchase price basically matches the placement price, making it arguably the most cost-effective moment to scoop up bargains. If it's merely a symbolic show of confidence, HK$120 million in real money feels a bi

On August 20, 2026, an anonymous large language model named "Ox Alpha" suddenly topped the OpenRouter leaderboard and set a new record for single‑day usage. Since "Ox" translates to "bull" in Chinese, and it happened to coincide with the popularity of the movie Niu Lai (Bull Comes), netizens gave it the down‑to‑earth nickname "Niu Lai Model." The model immediately drew widespread attention—not only because of the mystery shrouding its anonymous creators, but also due to its undeniable hardcore capabilities. The technical specs of the Niu Lai model are truly impressive: it boasts an ultra‑long context window of 1,048,600 tokens, enough to accommodate a medium‑sized codebase. Programmers who tested it found that on certain tasks its performance can match or even surpass the well‑known model

$XPeng Inc.(XPEV)$ Released Its 2026 Q2 Earnings This Afternoon; Overall Performance Was Mediocre, and U.S. Pre-Market Shares Dropped Nearly 4% After the Report. The results show that for the second quarter of 2026, revenue came in at RMB 19.74 billion, up 8% year-over-year and 51.5% quarter-over-quarter, missing the consensus estimate of RMB 20.2 billion. Gross margin was 20.7%, an increase of 3.4 percentage points from the same period last year and above the consensus estimate of 19.15%. On an adjusted basis, the comparable net loss was RMB -1.237 billion, far worse than the expected loss of RMB -0.767 billion. The profit shortfall was mainly due to a swing from gain to loss on a long-term investment, creating a paper loss of app

This morning, $Alibaba(BABA)$'s stock price plunged over 10% at one point, nearing the HK$110 level, which dragged the Hang Seng Tech Index down by 2.5%. On the news front, Alibaba Group raised approximately HK$80 billion (US$10.2 billion) through the largest stock placement in Hong Kong market history, underscoring the company's determination to raise and deploy substantial funds in its bid for global AI leadership. The giant, which has pivoted from online retail to the AI arena, placed 710 million new shares at HK$112.7 each, an 8.4% discount to last Friday's closing price in Hong Kong. In terms of dilution, based on public data estimating Alibaba's total outstanding Hong Kong shares at about 20.4 billion, the newly issued 710 mi

$MINIMAX-W(00100)$ rose more than 14% intraday today, currently trading at 353.0. On August 18, MiniMax was included in the Hong Kong Stock Connect and the Hang Seng TECH 100 Index, which enhanced its market liquidity and visibility. Previously, there had been no pure-play large model concept stocks available to mainland investors. On August 20, MiniMax launched MiniMax Design, a multimodal creative Agent workspace. The product is positioned as a "Harness" architecture that translates multimodal large models into actual productive capabilities. The goal is to transform the capabilities of its latest video model H3 into a complete workflow that can be directly applied to commercial content production. This move pushes the model tow

$XIAOMI-W(01810)$'s stock price rose nearly 4% today, continuing its winning streak since the release of its earnings report, with total gains approaching 11%. On the news front, Xiaomi just released its Q2 earnings report two days ago. Against the backdrop of high memory prices and a pressured consumer terminal market, Xiaomi's core smartphone business remained resilient, with gross margins in the handset business delivering a surprise upside that beat market expectations. In addition, Xiaomi just unveiled its new-generation humanoid robot "CyberOne" at the 2026 World Robot Conference, marking its first public appearance. The robot has already entered automotive factories for "internships" — at the self-tapping screw station, its